Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Growth 2020-2025
According to this study, over the next five years the Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19), covering the supply chain analysis, impact assessment to the Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market size growth rate in several scenarios, and the measures to be undertaken by Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
1g/20ml
1.25g/25ml
2.5g/50ml
5g/100ml
10g/200ml
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Clinic
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Boya-Bio
Beijing Tiantan Biological Products
Guangdong Shuagnlin Bio-pharmacy
Weiguang Biological
Hualan Bio
CTBB
Sinopharm
Nanyue Biopharming
Shanghai RAAS
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market by identifying its various subsegments.
Focuses on the key global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2015-2025
2.1.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption CAGR by Region
2.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Type
2.2.1 1g/20ml
2.2.2 1.25g/25ml
2.2.3 2.5g/50ml
2.2.4 5g/100ml
2.2.5 10g/200ml
2.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Type
2.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type (2015-2020)
2.3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue and Market Share by Type (2015-2020)
2.3.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Type (2015-2020)
2.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Application
2.5.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type (2015-2020)
2.5.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value and Market Share by Type (2015-2020)
2.5.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Type (2015-2020)
3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Company
3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Company
3.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Company (2018-2020)
3.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Company (2018-2020)
3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Company
3.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Company (2018-2020)
3.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Company (2018-2020)
3.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Company
3.4 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Regions
4.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Regions
4.2 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth
4.3 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth
4.4 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth
4.5 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth
5 Americas
5.1 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Countries
5.1.1 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Countries (2015-2020)
5.1.2 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value by Countries (2015-2020)
5.2 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Type
5.3 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Regions
6.1.1 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Regions (2015-2020)
6.1.2 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value by Regions (2015-2020)
6.2 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Type
6.3 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Countries
7.1.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Countries (2015-2020)
7.1.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value by Countries (2015-2020)
7.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Type
7.3 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Countries
8.1.1 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value by Countries (2015-2020)
8.2 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Type
8.3 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors
10.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customer
11 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Forecast
11.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Forecast (2021-2025)
11.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecast by Regions
11.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecast by Regions (2021-2025)
11.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast byRegions
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecast by Type
11.8 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecast by Application
12 Key Players Analysis
12.1 Boya-Bio
12.1.1 Company Information
12.1.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
12.1.3 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Boya-Bio Latest Developments
12.2 Beijing Tiantan Biological Products
12.2.1 Company Information
12.2.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
12.2.3 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Beijing Tiantan Biological Products Latest Developments
12.3 Guangdong Shuagnlin Bio-pharmacy
12.3.1 Company Information
12.3.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
12.3.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Guangdong Shuagnlin Bio-pharmacy Latest Developments
12.4 Weiguang Biological
12.4.1 Company Information
12.4.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
12.4.3 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Weiguang Biological Latest Developments
12.5 Hualan Bio
12.5.1 Company Information
12.5.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
12.5.3 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Hualan Bio Latest Developments
12.6 CTBB
12.6.1 Company Information
12.6.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
12.6.3 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 CTBB Latest Developments
12.7 Sinopharm
12.7.1 Company Information
12.7.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
12.7.3 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Sinopharm Latest Developments
12.8 Nanyue Biopharming
12.8.1 Company Information
12.8.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
12.8.3 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Nanyue Biopharming Latest Developments
12.9 Shanghai RAAS
12.9.1 Company Information
12.9.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
12.9.3 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Shanghai RAAS Latest Developments
13 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of 1g/20ml
Table 5. Major Players of 1.25g/25ml
Table 6. Major Players of 2.5g/50ml
Table 7. Major Players of 5g/100ml
Table 8. Major Players of 10g/200ml
Table 9. Global Consumption Sales by Type (2015-2020)
Table 10. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type (2015-2020)
Table 11. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2015-2020) ($ million)
Table 12. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Type (2015-2020) ($ Millions)
Table 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Type (2015-2020)
Table 14. Global Consumption Sales by Application (2015-2020)
Table 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Application (2015-2020)
Table 16. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value by Application (2015-2020)
Table 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Application (2015-2020)
Table 18. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Application (2015-2020)
Table 19. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Company (2017-2019) (K Units)
Table 20. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Company (2017-2019)
Table 21. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Company (2017-2019) ($ Millions)
Table 22. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Company (2017-2019)
Table 23. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Company (2017-2019)
Table 24. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base Distribution and Sales Area by Manufacturers
Table 25. Players Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Products Offered
Table 26. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 27. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Regions 2015-2020 (K Units)
Table 28. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Regions 2015-2020
Table 29. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value by Regions 2015-2020 ($ Millions)
Table 30. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Regions 2015-2020
Table 31. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Countries (2015-2020) (K Units)
Table 32. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Countries (2015-2020)
Table 33. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value by Countries (2015-2020) ($ Millions)
Table 34. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Countries (2015-2020)
Table 35. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Type (2015-2020) (K Units)
Table 36. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type (2015-2020)
Table 37. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Application (2015-2020) (K Units)
Table 38. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Application (2015-2020)
Table 39. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Regions (2015-2020) (K Units)
Table 40. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Regions (2015-2020)
Table 41. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value by Regions (2015-2020) ($ Millions)
Table 42. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Regions (2015-2020)
Table 43. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Type (2015-2020) (K Units)
Table 44. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type (2015-2020)
Table 45. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Application (2015-2020) (K Units)
Table 46. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Application (2015-2020)
Table 47. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Countries (2015-2020) (K Units)
Table 48. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Countries (2015-2020)
Table 49. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value by Countries (2015-2020) ($ Millions)
Table 50. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Countries (2015-2020)
Table 51. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Type (2015-2020) (K Units)
Table 52. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type (2015-2020)
Table 53. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Application (2015-2020) (K Units)
Table 54. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Application (2015-2020)
Table 55. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Countries (2015-2020) (K Units)
Table 56. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value by Countries (2015-2020) ($ Millions)
Table 58. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Countries (2015-2020)
Table 59. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Type (2015-2020) (K Units)
Table 60. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type (2015-2020)
Table 61. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption by Application (2015-2020) (K Units)
Table 62. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Application (2015-2020)
Table 63. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors List
Table 64. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customer List
Table 65. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Forecast by Countries (2021-2025) (K Units)
Table 66. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Forecast by Regions
Table 67. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Forecast by Countries (2021-2025) ($ Millions)
Table 68. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share Forecast by Regions
Table 69. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Forecast by Type (2021-2025) (K Units)
Table 70. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share Forecast by Type (2021-2025)
Table 71. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Forecast by Type (2021-2025) ($ Millions)
Table 72. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share Forecast by Type (2021-2025)
Table 73. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Forecast by Application (2021-2025) (K Units)
Table 74. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share Forecast by Application (2021-2025)
Table 75. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Forecast by Application (2021-2025) ($ Millions)
Table 76. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share Forecast by Application (2021-2025)
Table 77. Boya-Bio Product Offered
Table 78. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 79. Boya-Bio Main Business
Table 80. Boya-Bio Latest Developments
Table 81. Boya-Bio Basic Information, Company Total Revenue (in $ million), Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors
Table 82. Beijing Tiantan Biological Products Product Offered
Table 83. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 84. Beijing Tiantan Biological Products Main Business
Table 85. Beijing Tiantan Biological Products Latest Developments
Table 86. Beijing Tiantan Biological Products Basic Information, Company Total Revenue (in $ million), Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors
Table 87. Guangdong Shuagnlin Bio-pharmacy Product Offered
Table 88. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 89. Guangdong Shuagnlin Bio-pharmacy Main Business
Table 90. Guangdong Shuagnlin Bio-pharmacy Latest Developments
Table 91. Guangdong Shuagnlin Bio-pharmacy Basic Information, Company Total Revenue (in $ million), Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors
Table 92. Weiguang Biological Product Offered
Table 93. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 94. Weiguang Biological Main Business
Table 95. Weiguang Biological Latest Developments
Table 96. Weiguang Biological Basic Information, Company Total Revenue (in $ million), Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors
Table 97. Hualan Bio Product Offered
Table 98. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 99. Hualan Bio Main Business
Table 100. Hualan Bio Latest Developments
Table 101. Hualan Bio Basic Information, Company Total Revenue (in $ million), Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors
Table 102. CTBB Product Offered
Table 103. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 104. CTBB Main Business
Table 105. CTBB Latest Developments
Table 106. CTBB Basic Information, Company Total Revenue (in $ million), Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors
Table 107. Sinopharm Product Offered
Table 108. Sinopharm Basic Information, Company Total Revenue (in $ million), Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors
Table 109. Sinopharm Main Business
Table 110. Sinopharm Latest Developments
Table 111. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 112. Nanyue Biopharming Product Offered
Table 113. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 114. Nanyue Biopharming Main Business
Table 115. Nanyue Biopharming Latest Developments
Table 116. Nanyue Biopharming Basic Information, Company Total Revenue (in $ million), Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors
Table 117. Shanghai RAAS Product Offered
Table 118. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 119. Shanghai RAAS Main Business
Table 120. Shanghai RAAS Latest Developments
Table 121. Shanghai RAAS Basic Information, Company Total Revenue (in $ million), Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Figure 2. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of 1g/20ml
Figure 7. Product Picture of 1.25g/25ml
Figure 8. Product Picture of 2.5g/50ml
Figure 9. Product Picture of 5g/100ml
Figure 10. Product Picture of 10g/200ml
Figure 11. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type (2015-2020)
Figure 12. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Type (2015-2020)
Figure 13. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumed in Hospital
Figure 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Hospital (2015-2020) (K Units)
Figure 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Hospital (2015-2020) ($ Millions)
Figure 16. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumed in Clinic
Figure 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Clinic (2015-2020) (K Units)
Figure 18. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Clinic (2015-2020) ($ Millions)
Figure 19. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumed in Others
Figure 20. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Others (2015-2020) (K Units)
Figure 21. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Others (2015-2020) ($ Millions)
Figure 22. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Application (2015-2020)
Figure 23. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Application (2015-2020)
Figure 24. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Company in 2017
Figure 25. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Company in 2019
Figure 26. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Company in 2017
Figure 27. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Company in 2019
Figure 28. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Company in 2019
Figure 29. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Regions 2015-2020
Figure 30. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Regions 2015-2020
Figure 31. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2015-2020 (K Units)
Figure 32. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2015-2020 ($ Millions)
Figure 33. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2015-2020 (K Units)
Figure 34. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2015-2020 ($ Millions)
Figure 35. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2015-2020 (K Units)
Figure 36. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2015-2020 ($ Millions)
Figure 37. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2015-2020 (K Units)
Figure 38. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2015-2020 ($ Millions)
Figure 39. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Countries in 2019
Figure 40. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Countries in 2019
Figure 41. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type in 2019
Figure 42. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Application in 2019
Figure 43. United States Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 44. United States Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 45. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 46. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 47. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 48. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 49. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Countries in 2019
Figure 50. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Regions in 2019
Figure 51. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type in 2019
Figure 52. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Application in 2019
Figure 53. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 54. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 55. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 56. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 57. Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 58. Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 59. Southeast Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 60. Southeast Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 61. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 62. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 63. Australia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 64. Australia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 65. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Countries in 2019
Figure 66. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Countries in 2019
Figure 67. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type in 2019
Figure 68. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Application in 2019
Figure 69. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 70. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 71. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 72. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 73. UK Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 74. UK Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 75. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 76. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 77. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 78. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 79. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Countries in 2019
Figure 80. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Market Share by Countries in 2019
Figure 81. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Type in 2019
Figure 82. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Application in 2019
Figure 83. Egypt Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 84. Egypt Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 85. South Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 86. South Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 87. Israel Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 88. Israel Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 89. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 90. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 91. GCC Countries Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth 2015-2020 (K Units)
Figure 92. GCC Countries Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth 2015-2020 ($ Millions)
Figure 93. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 94. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 95. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 96. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 97. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 98. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 99. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 100. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 101. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 102. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 103. United States Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 104. United States Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 105. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 106. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 107. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 108. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 109. Brazil Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 110. Brazil Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 111. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 112. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 113. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 114. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 115. Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 116. Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 117. Southeast Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 118. Southeast Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 119. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 120. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 121. Australia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 122. Australia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 123. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 124. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 125. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 126. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 127. UK Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 128. UK Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 129. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 130. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 131. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 132. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 133. Spain Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 134. Spain Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 135. Egypt Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 136. Egypt Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 137. South Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 138. South Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 139. Israel Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 140. Israel Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 141. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 142. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 143. GCC Countries Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption 2021-2025 (K Units)
Figure 144. GCC Countries Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value 2021-2025 ($ Millions)
Figure 145. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share (2018-2020)
Figure 146. Beijing Tiantan Biolog
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets